Skip to main content
Natco Pharma Ltd. logo

Natco Pharma Ltd. — Investor Relations & Filings

Ticker · NATCOPHARM ISIN · INE987B01026 LEI · 33580086GIBRWXSNGG39 BSE.NS Manufacturing
Open in API
Filings indexed 1,708 across all filing types
Latest filing 2020-10-15 Regulatory Filings
Country IN India
Listing BSE.NS NATCOPHARM

About Natco Pharma Ltd.

https://www.natcopharma.co.in/

Natco Pharma Ltd. is a vertically integrated organization focused on the development, manufacturing, and marketing of complex generics and active pharmaceutical ingredients (APIs). The company specializes in niche therapeutic areas, maintaining a leadership position in oncology and a significant presence in specialty segments such as hepatology, cardiology, and diabetology. Natco is recognized for its expertise in high-barrier-to-entry products, including complex oral solids and injectables. Its business model emphasizes research and development to deliver affordable versions of life-saving medicines globally. With a robust portfolio of finished dosage formulations and a strong supply chain for APIs, the company serves diverse international markets, including North America, Europe, and emerging economies, through strategic partnerships and direct distribution channels.

Recent filings

Filing Released Lang Actions
Outcome and Proceedings of the 37th Annual General Meeting
Regulatory Filings
2020-10-15 English
PCS Compliance certificate for the period ended 30th September,2020
Regulatory Filings
2020-10-06 English
Press Release
Regulatory Filings Classification · 90% confidence The document text contains only placeholders for images and no substantive text content. The total length is only 226 characters, which is very short and contains no financial data, report content, or announcements. There is no indication of any report, announcement, or filing type. Given the lack of content, this document cannot be classified as a report or detailed filing. It is most consistent with a Regulatory Filing (RNS) as a fallback category for miscellaneous or non-informative filings.
2020-09-30 English
NATCO announces launch of breast cancer medicine Lapatinib Tablets in the U.S
Regulatory Filings
2020-09-30 English
Closure of Trading window remain closed for the Directors, Promoters and Designated persons covered under SEBI (PIT) Regulations, 2015
Regulatory Filings
2020-09-30 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a short notice informing stock exchanges about the closure of the trading window for insiders ahead of the announcement of quarterly financial results. It mentions the upcoming declaration of financial results for the quarter ended September 30, 2020, but does not contain any financial data or the results themselves. It is an announcement related to compliance with insider trading regulations rather than a financial report or earnings release. The document length is only 1241 characters, indicating it is a brief notice. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2020-09-30 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.